Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGenetic & Molecular TestingCarolina Behavioral Kidney Testing Coverage | Open…
    Ask Trek AI about this page
    ModifiedCarolina Behavioral Health Alliance (CBHA)Policy N/A

    Genetic Testing: Kidney Disorders

    Customize your policy alerts

    Sign up for all carolinabehavioralhealth policy alerts

    Know when carolinabehavioralhealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage criteria for genetic and molecular testing used to establish or confirm inherited kidney disorders, evaluate APOL1-mediated kidney disease, and monitor kidney transplant rejection using donor-derived cell-free DNA.

    Policy Summary
    PayerCarolina Behavioral Health Alliance (CBHA)
    PolicyGenetic Testing: Kidney Disorders
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument transplant status, clinical suspicion or assessment of rejection, the intended role of donor-derived cell-free DNA testing, and relevant biopsy information when applicable.
    SourceLink
    POLICY UPDATE CHANGES

    Donor-derived cell-free DNA testing for kidney transplant rejection changed from non-covered to covered.

    Comprehensive kidney disease panel criteria were expanded to include syndromic or multisystem features and the possibility of identifying a condition amenable to targeted treatment.

    Polycystic kidney disease panel criteria removed intracranial aneurysm, poor corticomedullary differentiation, hepatobiliary abnormalities with progressive portal hypertension, and congenital hepatic fibrosis with portal hypertension.

    Polycystic kidney disease targeted variant analysis was retired and testing for this condition is now reviewed under the General policy.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4Defined clinical indication groups
    8Listed genetic kidney disorders
    12 monthsMinimum testing interval
    3Post-transplant monitoring circumstances
    3APOL1 high-risk genotypes

    Covered Testing Criteria

    Polycystic Kidney Disease Panels

    Covered when the member has at least one listed clinical feature.

    Polycystic kidney disease clinical features

    • Multiple bilateral renal cysts are present.
    • Extrarenal cysts: Cysts are present in organs other than the kidneys, especially the liver, seminal vesicles, pancreas, or arachnoid membrane.
    • Early hypertension: The individual has hypertension younger than age 35.younger than age 35
    • Enlarged echogenic kidneys: The kidneys are bilaterally enlarged and diffusely echogenic.

    Polycystic Kidney Disease Panel Investigational Indications

    Testing is investigational for all other indications.

    Other indications: Polycystic kidney disease panel testing is investigational when none of the specified clinical features is present.

    APOL1 Targeted Variant Analysis

    Covered when all requirements are met.

    APOL1 targeted variant analysis

    • Kidney disease: The member has kidney disease.
    • Qualifying APOL1 risk context

      • African ancestry: The member is of African ancestry.
      • Family APOL1 genotype: A family member has a confirmed APOL1 high-risk genotype: G1/G1, G1/G2, or G2/G2.G1/G1, G1/G2, or G2/G2

    Comprehensive Kidney Disease Panels

    Covered when all requirements are met.

    Comprehensive kidney disease panel

    • Undetermined cause after workup: The member has chronic kidney disease with an undetermined cause after undergoing standard-of-care workup studies.

      Standard-of-care workup may include history and physical examination, biochemical testing, renal imaging, or renal biopsy.

    • Qualifying comprehensive-panel feature

      • Early onset: Chronic kidney disease onset occurred under 40 years of age.under 40 years of age
      • Affected relatives: One or more first- or second-degree relatives have chronic kidney disease.

    Comprehensive Kidney Disease Panel Investigational Indications

    Testing is investigational for all other indications.

    Other indications: Comprehensive kidney disease panel testing is investigational when the specified undetermined-cause and qualifying-feature requirements are not met.

    Donor-Derived Cell-free DNA for Kidney Transplant Rejection

    Covered when all requirements are met and at least one monitoring circumstance applies.

    Post-kidney-transplant donor-derived cell-free DNA

    • Kidney transplantation: The member has undergone kidney transplantation.
    • Testing interval: The test has not been performed in the previous 12 months.not performed in the previous 12 months
    • Qualifying transplant circumstance

      • Clinical signs of acute rejection: The member has clinical signs of acute rejection.

    Other Covered Kidney Disorders

    Covered when the member demonstrates clinical features consistent with the disorder.

    Other covered genetic kidney disorders

    • Alport syndrome: Clinical features are consistent with Alport syndrome.
    • C3 glomerulopathy: Clinical features are consistent with C3 glomerulopathy.
    • Congenital nephrotic syndrome: Clinical features are consistent with congenital nephrotic syndrome.
    • Cystinosis: Clinical features are consistent with cystinosis.

    Other Kidney Disorders Requiring General Policy Review

    Other kidney disorders are evaluated under the general genetic testing policy.

    Other kidney disorders: Genetic testing to establish or confirm kidney disorders not specifically discussed in this policy or another medical policy is evaluated using the criteria in Genetic Testing: General Approach to Genetic and Molecular Testing.

    Other covered genetic kidney disorders

    Considered medically necessary when clinical features are consistent with the disorder.

    Listed genetic kidney disorders: Genetic testing to establish or confirm a diagnosis and guide management for Alport syndrome, C3 glomerulopathy, congenital nephrotic syndrome, cystinosis, cystinuria, Fabry disease, genetic or familial atypical hemolytic-uremic syndrome, or primary hyperoxaluria.Member demonstrates clinical features consistent with the disorder

    The list is not comprehensive.

    Other kidney disorders

    Other kidney disorders not specifically discussed in this policy or another medical policy are evaluated under the General Approach to Genetic and Molecular Testing policy.

    General-policy review: Genetic testing is used to establish or confirm the diagnosis of a kidney disorder not specifically addressed in this policy or another medical policy.Review under General Approach to Genetic and Molecular Testing criteria

    No disorder-specific criteria are provided in this section.

    Donor-derived cell-free DNA for kidney transplant rejection

    Donor-derived cell-free DNA testing may be covered for patients who have undergone solid-organ transplantation when used to evaluate or manage possible allograft rejection.

    Permitted intended use: The test assists in evaluating adequacy of immunosuppression in lieu of tissue biopsy when biopsy information would guide immunosuppression management; rules out active rejection in a validated population with clinical suspicion when deciding whether to obtain a biopsy; further evaluates allograft status after physician-assessed pretest probability; or assesses rejection after a biopsy that is inconclusive or limited by insufficient material.Patient has undergone solid-organ transplantation

    Testing should be used with other clinical evaluations and results.

    Routine post-transplant monitoring frequency

    For routine post-transplant monitoring without clear, specific, evidence-based frequency recommendations for a particular screening regimen.

    Default monitoring frequency: Coverage frequency defaults to once every 12 months.Once every 12 months

    This default applies absent a specific evidence-based guideline recommendation for a particular regimen.

    Polycystic kidney disease targeted variant analysis has been retired from this disorder-specific policy. Testing for polycystic kidney disease under the retired targeted-variant pathway is reviewed according to the General Approach to Genetic and Molecular Testing policy. This change does not exclude all polycystic kidney disease testing; the separate polycystic kidney disease panel criteria remain applicable when specified clinical features are present.

    Polycystic kidney disease panel testing — qualifying clinical features for establishing or confirming diagnosis

    Covered to establish or confirm a polycystic kidney disease diagnosis when at least one qualifying clinical feature is present.

    Qualifying clinical feature

    • Multiple bilateral renal cysts are present.
    • Cysts are present in organs other than the kidneys, especially the liver, seminal vesicles, pancreas, or arachnoid membrane.
    • The individual has hypertension younger than age 35.younger than age 35
    • The kidneys are bilaterally enlarged and diffusely echogenic.

    APOL1 targeted variant analysis — kidney disease with African ancestry or qualifying family genotype

    Covered when all requirements are met.

    APOL1 targeted variant analysis

    • The member has kidney disease.
    • Qualifying ancestry or family genotype

      • The member is of African ancestry.
      • A family member has a confirmed APOL1 high-risk genotype: G1/G1, G1/G2, or G2/G2.G1/G1, G1/G2, or G2/G2

    Comprehensive kidney disease panel testing — undetermined-cause chronic kidney disease after standard-of-care workup with qualifying features

    Covered when all requirements are met.

    Comprehensive kidney disease panel

    • The member has chronic kidney disease of undetermined cause after standard-of-care workup, which may include history and physical examination, biochemical testing, renal imaging, and renal biopsy when indicated.
    • Qualifying feature

      • Chronic kidney disease onset occurred under 40 years of age.under 40 years of age
      • One or more first- or second-degree relatives have chronic kidney disease.
      • There is a consanguineous family history.

    Peripheral blood donor-derived cell-free DNA after kidney transplantation — acute rejection signs, inconclusive biopsy, or immunosuppression monitoring

    Covered when all requirements are met and at least one qualifying circumstance applies.

    Peripheral blood donor-derived cell-free DNA after kidney transplantation

    • The member has undergone kidney transplantation.
    • The test has not been performed in the previous 12 months.not performed in the previous 12 months
    • Qualifying circumstance

      • The member has clinical signs of acute rejection.
      • A biopsy performed to check for signs of acute rejection is inconclusive.

    Genetic testing for listed kidney disorders — establish or confirm diagnosis when features are consistent and testing guides management

    Covered when clinical features are consistent with the suspected disorder and testing is intended to guide management.

    Listed kidney disorder

    • Clinical features are consistent with Alport syndrome.
    • Clinical features are consistent with C3 glomerulopathy.
    • Clinical features are consistent with congenital nephrotic syndrome.
    • Clinical features are consistent with cystinosis.
    • Clinical features are consistent with cystinuria.

    Establishing or confirming listed kidney disorder diagnoses — clinical consistency and management purpose

    Covered when all requirements are met.

    Diagnosis and management purpose

    • Suspected kidney disorder

      • Clinical features are consistent with Alport syndrome.
      • Clinical features are consistent with C3 glomerulopathy.
      • Clinical features are consistent with congenital nephrotic syndrome.
      • Clinical features are consistent with cystinosis.
      • Clinical features are consistent with cystinuria.

    Comprehensive genetic testing for kidney disease of unknown etiology — negative or inconclusive workup with elevated genetic-disease probability

    Covered when all requirements are met.

    Comprehensive genetic testing for kidney disease of unknown etiology

    • The individual has undergone biochemical and serologic testing, kidney imaging, and renal biopsy if indicated, with a negative or inconclusive nephrologic workup.Initial nephrologic workup completed
    • Elevated probability of genetic disease

      • Early-onset disease is present.Age <40 years
      • There is a positive family history of chronic kidney disease.

    Donor-derived cell-free DNA testing — evaluation and management of kidney allograft injury or rejection after transplantation

    Covered for evaluation and management of kidney allograft injury or rejection after transplantation.

    Post-transplant allograft evaluation

    • The patient has undergone kidney transplantation.
    • Permitted intended use

      • The test assists in evaluating adequacy of immunosuppression in lieu of tissue biopsy when biopsy information would guide an immunosuppression management decision.
      • The test is used to rule out active rejection in a validated population with clinical suspicion when deciding whether to obtain a biopsy.
      • The test further evaluates allograft status after a physician-assessed pretest probability of rejection.

    Eligibility Requirements

    Eligibility for the covered services depends on the clinical context. APOL1 targeted variant analysis requires kidney disease and either African ancestry or a family member with a confirmed APOL1 high-risk genotype of G1/G1, G1/G2, or G2/G2. Comprehensive kidney disease panel testing requires chronic kidney disease of undetermined cause after an appropriate nephrologic workup, together with at least one qualifying clinical or genetic-risk feature. Donor-derived cell-free DNA testing requires prior kidney transplantation, no such test in the previous 12 months, and a qualifying transplant-monitoring circumstance.

    For comprehensive kidney disease panel testing, document that chronic kidney disease remains of undetermined cause after standard-of-care evaluation, which may include history and physical examination, biochemical and serologic testing, kidney imaging, and renal biopsy when indicated. The initial workup should be negative or inconclusive. At least one additional feature should increase the likelihood of a genetic cause, such as disease onset at under 40 years of age, affected first- or second-degree relatives, consanguinity, extrarenal anomalies, cystic renal disease, congenital nephropathy, syndromic or multisystem features, or the possibility of identifying a condition amenable to targeted treatment.

    Covered Services and Diagnosis Coding

    Polycystic Kidney Disease PanelsCPTCovered
    81404Polycystic kidney disease panel
    81405Polycystic kidney disease panel
    81406Polycystic kidney disease panel
    81407Polycystic kidney disease panel
    81408Polycystic kidney disease panel
    81479Polycystic kidney disease panel
    Comprehensive Kidney Disease PanelsCPTCovered
    81401Comprehensive kidney disease panel
    81402Comprehensive kidney disease panel
    81403Comprehensive kidney disease panel
    81404Comprehensive kidney disease panel
    81405Comprehensive kidney disease panel
    81406Comprehensive kidney disease panel
    81407Comprehensive kidney disease panel
    81408Comprehensive kidney disease panel
    81479Comprehensive kidney disease panel
    APOL1 Targeted Variant AnalysisCPTCovered
    0355UAPOL1 targeted variant analysis
    81479APOL1 targeted variant analysis
    Donor-Derived Cell-free DNA for Kidney Transplant RejectionCPTCovered
    81479Donor-derived cell-free DNA for kidney transplant rejection
    0493UDonor-derived cell-free DNA for kidney transplant rejection
    0118UDonor-derived cell-free DNA for kidney transplant rejection
    0508UDonor-derived cell-free DNA for kidney transplant rejection
    0509UDonor-derived cell-free DNA for kidney transplant rejection
    Donor-Derived Cell-free DNA Diagnosis CodesICD-10
    T86.11Kidney transplant rejection
    T86.12Kidney transplant failure
    Z94.0Kidney transplant status
    Other Covered Kidney DisordersCPTCovered
    81400Other covered kidney disorders genetic testing
    81401Other covered kidney disorders genetic testing
    81402Other covered kidney disorders genetic testing
    81403Other covered kidney disorders genetic testing
    81404Other covered kidney disorders genetic testing
    81405Other covered kidney disorders genetic testing
    81406Other covered kidney disorders genetic testing
    81407Other covered kidney disorders genetic testing
    81408Other covered kidney disorders genetic testing
    Polycystic Kidney Disease Panel Diagnosis CodesICD-10
    Q61Polycystic kidney disease panels common ICD code
    N18Polycystic kidney disease panels common ICD code
    Comprehensive Kidney Disease Panel Diagnosis CodesICD-10
    N00-N08Comprehensive kidney disease panels common ICD code range
    N10-N19Comprehensive kidney disease panels common ICD code range
    Q61Comprehensive kidney disease panels common ICD code
    R31Comprehensive kidney disease panels common ICD code
    APOL1 Targeted Variant Analysis Diagnosis CodesICD-10
    N00-N08APOL1 targeted variant analysis common ICD code range
    N10-N19APOL1 targeted variant analysis common ICD code range
    Coding Threshold
    Hypertension onset thresholdYounger than age 35
    Applicable testingPolycystic kidney disease panel testing
    Qualifying useA clinical feature supporting confirmation or establishment of a polycystic kidney disease diagnosis
    Coding Threshold
    Chronic kidney disease onset thresholdUnder 40 years of age

    Documentation and Review Guidance

    Documentation Required

    Document Clinical Features

    Document the clinical features supporting the suspected or confirmed genetic kidney disorder. Covered disorders include Alport syndrome, C3 glomerulopathy, congenital nephrotic syndrome, cystinosis, cystinuria, Fabry disease, genetic familial atypical hemolytic-uremic syndrome (aHUS), and primary hyperoxaluria; disorder-specific features should be supported by authoritative references such as GeneReviews, OMIM, or other scholarly sources.

    • Record the specific phenotype, relevant laboratory findings, organ involvement, age at onset, and suspected disorder.
    • For kidney disorders not specifically addressed by this policy, apply the criteria in the General Approach to Genetic and Molecular Testing policy.
    Documentation Required

    Document Prior Nephrologic Workup

    Before supporting comprehensive genetic testing for kidney disease of undetermined etiology, document the results of the initial nephrologic evaluation. The workup should be negative or inconclusive before the condition is treated as kidney disease of unknown etiology.

    Clinical Background

    Inherited kidney disorders range from relatively common conditions, such as autosomal dominant polycystic kidney disease, to rare disorders, including Lowe syndrome and Fabry disease. Identifying a genetic cause may direct treatment, inform family members, and clarify the cause of chronic kidney disease. Exome sequencing and comprehensive genetic panels are emerging diagnostic approaches, while donor-derived cell-free DNA offers a less invasive biomarker for monitoring kidney transplant graft injury or possible rejection.

    Key Definitions

    APOL1 High-Risk Genotype
    G1/G1APOL1 high-risk genotype
    G1/G2APOL1 high-risk genotype
    G2/G2APOL1 high-risk genotype
    Donor-Derived Cell-Free DNA
    Measurement typePeripheral blood measurement of donor-derived cell-free DNA
    TimingMeasured after renal transplantation
    Clinical purposeManagement and monitoring of possible rejection or adequacy of immunosuppression

    Investigational and Noncovered Uses

    The following uses are investigational or not covered under the applicable pathway: polycystic kidney disease panel testing without at least one specified clinical feature; comprehensive kidney disease panel testing without undetermined-cause chronic kidney disease after the required workup and a qualifying feature; APOL1 testing without kidney disease and a qualifying ancestry or family-history context; and donor-derived cell-free DNA testing after transplantation when the required interval or transplant-management indication is absent. Genetic testing for a listed kidney disorder is not supported when clinical features are inconsistent with the suspected condition. Kidney disorders not specifically addressed by this policy or another medical policy are reviewed under the General Approach to Genetic and Molecular Testing policy.

    Policy Summary
    PayerCarolina Behavioral Health Alliance (CBHA)
    PolicyGenetic Testing: Kidney Disorders
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument transplant status, clinical suspicion or assessment of rejection, the intended role of donor-derived cell-free DNA testing, and relevant biopsy information when applicable.
    SourceLink
    On This Page
    Covered Testing CriteriaEligibility RequirementsCovered Services and Diagnosis CodingDocumentation and Review GuidanceClinical BackgroundKey DefinitionsInvestigational and Noncovered Uses
  1. Consanguinity: There is a consanguineous family history.
  2. Cystic renal disease is present.
  3. Congenital nephropathy is present.
  4. Syndromic or multisystem features are present.
  5. Targeted treatment opportunity: There is a possibility of identifying a condition amenable to targeted treatment.
  6. Inconclusive biopsy: A biopsy was done to check for signs of acute rejection and is inconclusive.
  7. Immunosuppression monitoring: The member is being monitored for adequate immunosuppression.
  8. Cystinuria: Clinical features are consistent with cystinuria.
  9. Fabry disease: Clinical features are consistent with Fabry disease.
  10. Familial atypical hemolytic-uremic syndrome: Clinical features are consistent with genetic or familial atypical hemolytic-uremic syndrome.
  11. Primary hyperoxaluria: Clinical features are consistent with primary hyperoxaluria.
  12. Cystic renal disease is present.
  13. Congenital nephropathy is present.
  14. Syndromic or multisystem features are present.
  15. There is a possibility of identifying a condition amenable to targeted treatment.
  16. The member is being monitored for adequate immunosuppression.
    Clinical features are consistent with Fabry disease.
  17. Clinical features are consistent with genetic or familial atypical hemolytic-uremic syndrome.
  18. Clinical features are consistent with primary hyperoxaluria.
  19. Clinical features are consistent with Fabry disease.
  20. Clinical features are consistent with genetic or familial atypical hemolytic-uremic syndrome.
  21. Clinical features are consistent with primary hyperoxaluria.
  22. Testing is used to establish or confirm the diagnosis and guide management.
  23. There is consanguinity.
  24. Extrarenal anomalies or multisystem features are present.
  25. Cystic renal disease or congenital nephropathy is present.
  26. There is a possibility of identifying a condition amenable to targeted treatment.
  27. The test assesses rejection after a biopsy that is inconclusive or limited by insufficient material.
    Applicable testingComprehensive kidney disease panel testing
    Required contextChronic kidney disease has an undetermined cause after standard-of-care workup
    Coding Threshold
    Prior testing intervalNot performed in the previous 12 months
    Applicable testingPeripheral blood donor-derived cell-free DNA measurement after kidney transplantation
    Additional requirementThe member has undergone kidney transplantation and has a qualifying transplant-monitoring circumstance
    Coding Threshold
    Routine monitoring frequencyOnce every 12 months
    Applicable settingRoutine post-transplant monitoring
    When this default appliesAbsent clear, specific, evidence-based guideline recommendations for a particular screening regimen
    Coding Threshold
    Early-onset thresholdAge <40 years
    Applicable testingComprehensive kidney disease genetic testing
    Clinical contextKidney disease of unknown etiology after a negative or inconclusive initial nephrologic workup
  28. History and physical examination.
  29. Biochemical and serologic testing.
  30. Renal imaging.
  31. Renal biopsy when indicated.
  32. Documentation Required

    Document Genetic-Risk Rationale

    Explain why a genetic cause is reasonably suspected by documenting the applicable genetic-risk features. Higher-yield indications include early-onset disease, family history, consanguinity, extrarenal or multisystem findings, cystic or congenital nephropathy, and a reasonable possibility of identifying an actionable condition.

    • Chronic kidney disease onset before age 40.
    • One or more first- or second-degree relatives with chronic kidney disease.
    • Consanguineous family history.
    • Cystic renal disease or congenital nephropathy.
    • Extrarenal anomalies or syndromic/multisystem features.
    • A condition amenable to targeted treatment may be identified.
    • Also document other circumstances in which testing may be particularly informative, such as a high prevalence of monogenic disease in the clinical category or advanced disease in which biopsy would not be informative.
    Documentation Required

    Document Transplant-Rejection Evaluation

    For donor-derived cell-free DNA testing after kidney transplantation, document the transplant status, the clinical purpose of testing, and the rejection-related circumstances supporting its use.

    • Member has undergone kidney transplantation.
    • The test has not been performed within the previous 12 months.
    • Document clinical signs of acute rejection, an inconclusive biopsy performed to assess acute rejection, or monitoring for adequate immunosuppression.
    • Use the result with the standard clinical assessment and document how it informs evaluation or management of allograft injury or rejection.
    Prior Authorization

    Polycystic Kidney Disease Panel Indication

    Polycystic kidney disease panel testing (81404, 81405, 81406, 81407, 81408, 81479) is medically necessary to confirm or establish polycystic kidney disease when the member has at least one covered clinical feature. All other indications are investigational.

    • Multiple bilateral renal cysts.
    • Cysts in organs other than the kidneys, especially the liver, seminal vesicles, pancreas, or arachnoid membrane.
    • Hypertension in an individual younger than 35 years.
    • Bilaterally enlarged and diffusely echogenic kidneys.
    • Do not support the panel as medically necessary when none of these features is documented.
    Prior Authorization

    APOL1 Testing Indication

    APOL1 targeted variant analysis for the high-risk genotype G1/G1, G1/G2, or G2/G2 (0355U, 81479) is medically necessary when kidney disease is present and the member is of African ancestry or has a family member with a confirmed APOL1 high-risk genotype. All other indications are investigational.

    • Document the kidney disease diagnosis.
    • Document African ancestry or a family member's confirmed G1/G1, G1/G2, or G2/G2 genotype.
    • Do not support targeted APOL1 testing for other indications.
    Prior Authorization

    Comprehensive Panel Indication

    A comprehensive kidney disease panel (81401, 81402, 81403, 81404, 81405, 81406, 81407, 81408, 81479) is medically necessary when chronic kidney disease has an undetermined cause after standard-of-care workup and at least one qualifying genetic-risk feature is documented. Other indications are investigational.

    • Document negative or inconclusive history and physical examination, biochemical and serologic testing, renal imaging, and renal biopsy when indicated.
    • Document at least one of: CKD onset before age 40; first- or second-degree relative with CKD; consanguinity; cystic renal disease; congenital nephropathy; syndromic or multisystem features; or potential to identify a targeted-treatment condition.
    • Testing may be particularly informative when biopsy would not be informative because of advanced disease.
    Prior Authorization

    Post-Transplant dd-cfDNA Indication

    Verify that donor-derived cell-free DNA testing is being used after kidney transplantation for an appropriate rejection or immunosuppression-management purpose, and that the test has not been performed during the preceding 12 months.

    • Confirm kidney transplantation.
    • Document clinical signs of acute rejection, an inconclusive or limited biopsy, monitoring of adequate immunosuppression, or a physician-assessed pretest concern requiring further allograft-status evaluation.
    • The intended use may include assessing immunosuppression adequacy, ruling in or out rejection when considering biopsy, further evaluating allograft rejection probability, or assessing rejection after inconclusive biopsy results.
    Denial Risk

    Denial Risk: No Consistent Clinical Features

    Genetic testing to establish or confirm a listed genetic kidney disorder is at risk for denial when the record does not demonstrate clinical features consistent with the suspected disorder. Clinical features should be specific to the disorder and supported by appropriate clinical references.

    • Do not rely solely on a nonspecific kidney disease diagnosis without a compatible phenotype.
    • Testing for disorders not specifically addressed by the policy must satisfy the General Approach to Genetic and Molecular Testing criteria.

    Unsupported block type: denial_risk başાassisting? no

    Denial Risk

    Denial Risk: Unsupported Transplant-Rejection Use

    Do not support donor-derived cell-free DNA testing as medically necessary when it lacks an intended rejection-evaluation or immunosuppression-management purpose. The test must be considered with standard clinical assessments and other relevant results, including biopsy findings when available.

    • Document the clinical rationale for evaluating active rejection, immunosuppression adequacy, or allograft status.
    • Testing for other post-transplant purposes is investigational.
    Documentation Required

    Provider Actions: Ordering and Transplant-Center Requirements

    Ensure that donor-derived cell-free DNA testing is ordered by a qualified physician considering the diagnosis of active rejection and affiliated with a transplant center. Document the intended use and integrate the result with standard clinical evaluation rather than using it as a stand-alone determination.

    • The test may help rule in or rule out rejection when assessing the need for or results of diagnostic biopsy.
    • It may be particularly useful when invasive procedures have significant contraindications.
    • Document the transplant-center affiliation and physician's rejection-related assessment.
    Close Relatives
    Close relativesFirst-, second-, and third-degree blood relatives on the same side of the family
    First-degree relativesParents, siblings, and children
    Second-degree relativesGrandparents, aunts, uncles, nieces, nephews, grandchildren, and half siblings